| Literature DB >> 32201112 |
Zixuan Cai1, Ting Ye1, Xing Xu1, Minhui Gao2, Yaru Zhang1, Dan Wang1, Yiming Gu1, Haojie Zhu1, Lijuan Tong1, Jiashu Lu3, Zhuo Chen4, Chao Huang5.
Abstract
The decrease of microglia in the hippocampus is a novel mechanism for depression onset. Reversal of this decrease can ameliorate stress-induced depression-like behaviors in rodents. However, the property of this therapeutic strategy remains unclear. We addressed this issue by designing a series of behavioral experiments. Results showed that a single lipopolysaccharide (LPS) injection at the dose of 75 and 100 μg/kg, but not at 30 or 50 μg/kg, produced obvious antidepressant effects in chronic unpredictable stress (CUS) mice at 5 h after the drug administration. In the time-dependent experiment, a single LPS injection (100 μg/kg) ameliorated the CUS-induced depression-like behaviors in mice at 5 and 8 h, but not at 3 h, after the drug administration. The antidepressant effect of a single LPS injection persisted at least 10 days and disappeared at 14 days after the drug administration. 14 days after the first injection, a second LPS injection (100 μg/kg) still produced antidepressant effects in chronically-stressed mice who re-displayed depression-like behaviors at 5 h after the drug administration. The antidepressant effect of LPS appears to be dependent on microglia, as at 5 h after LPS administration (100 μg/kg), the CUS-induced decrease in microglial numbers and Iba-1 mRNA levels in the hippocampus was reversed markedly, and inhibition of microglia by minocycline (40 mg/kg) or PLX33297 (290 mg/kg) prevented the antidepressant effect of LPS in CUS mice. These results indicate that a single LPS injection displays rapid and sustained antidepressant effects in chronically stressed mice likely through stimulating hippocampal microglia.Entities:
Keywords: Depression; Lipopolysaccharide; Microglia; Minocycline; PLX3397
Mesh:
Substances:
Year: 2020 PMID: 32201112 DOI: 10.1016/j.pnpbp.2020.109931
Source DB: PubMed Journal: Prog Neuropsychopharmacol Biol Psychiatry ISSN: 0278-5846 Impact factor: 5.067